ArticleOncogene2026
USP20-mediated PGAM1 stabilization promotes glycolysis and confers osimertinib resistance in non-small cell lung carcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Osimertinib resistance poses a significant clinical challenge in treating non-small cell lung carcinoma (NSCLC) patients harboring EGFR-activating or T790M mutations, highlighting the urgent need to elucidate the underlying molecular mechanisms. In this study, we show that elevated USP20 expression drives osimertinib resistance and is associated with poor clinical outcomes in osimertinib-resistant NSCLC. Mechanistically, USP20 specifically interacts with PGAM1 and catalyzes the removal of K225-linked ubiquitin chains through its C154 catalytic site, thereby stabilizing PGAM1 to enhance glycolysis and promote osimertinib resistance. Importantly, through extensive virtual drug screening, we identified compound 89131-02-2 as a novel and selective inhibitor that targets the USP20 C154 catalytic site. Pharmacological inhibition of USP20 by 89131-02-2 effectively suppressed glycolysis and restored osimertinib sensitivity in functional assays. Our findings not only establish the USP20-PGAM1 axis as a key mediator of osimertinib response but also offer a potential therapeutic strategy to overcome resistance in NSCLC patients.
Indexed as
Identifiers
42420587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.